{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T01:05:33Z","timestamp":1789693533066,"version":"4.0.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100022828","name":"Emory University Center for Reproductive Health Research in the Southeast","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022828","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007186","name":"University of California Los Angeles Jonsson Comprehensive Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007186","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ygyno.2026.08.015","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T15:55:13Z","timestamp":1787327713000},"page":"181-187","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Early-phase vs. late-phase clinical trials in gynecologic oncology: Trends in trial completion, reporting, and enrollment of racial and ethnic minority groups"],"prefix":"10.1016","volume":"212","author":[{"given":"Michael T.","family":"Richardson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danika","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jecca R.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Holder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vineeth","family":"Thirunavu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naixin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon E.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5757-9832","authenticated-orcid":false,"given":"Christopher J.","family":"Magnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Marie P.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie F.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie A.","family":"Squires","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill N.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth Y.","family":"Karlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.","family":"Kapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario R.","family":"Roque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritu","family":"Salani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ygyno.2026.08.015_bb0005","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","article-title":"Estimation of clinical trial success rates and related parameters","volume":"20","author":"Wong","year":"2019","journal-title":"Biostatistics"},{"issue":"7","key":"10.1016\/j.ygyno.2026.08.015_bb0010","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","article-title":"Why 90% of clinical drug development fails and how to improve it?","volume":"12","author":"Sun","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.ygyno.2026.08.015_bb0015","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of Trastuzumab Deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2026.08.015_bb0020","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ygyno.2018.08.037","article-title":"A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice","volume":"151","author":"Jazaeri","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2026.08.015_bb0025","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ygyno.2010.02.008","article-title":"Phase I clinical trials in 85 patients with gynecologic cancer: the M. D. Anderson Cancer center experience","volume":"117","author":"Moroney","year":"2010","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2026.08.015_bb0030","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1097\/AOG.0000000000004735","article-title":"Early discontinuation, results reporting, and publication of gynecology clinical trials from 2007 to 2020","volume":"139","author":"Steinberg","year":"2022","journal-title":"Obstet. Gynecol."},{"issue":"6","key":"10.1016\/j.ygyno.2026.08.015_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajogmf.2022.100696","article-title":"How many US obstetrical trials reach publication? A cross-sectional analysis of ClinicalTrials.gov and PubMed from 2007 to 2019","volume":"4","author":"DiTosto","year":"2022","journal-title":"Am. J. Obstet. Gynecol. MFM"},{"issue":"1","key":"10.1016\/j.ygyno.2026.08.015_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajogmf.2020.100253","article-title":"The obstetrical research landscape: a cross-sectional analysis of clinical trials from 2007-2020","volume":"3","author":"Steinberg","year":"2021","journal-title":"Am J Obstet Gynecol MFM."},{"issue":"1","key":"10.1016\/j.ygyno.2026.08.015_bb0045","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/GRF.0000000000000765","article-title":"Enrollment of racial and ethnic minoritized groups in gynecologic oncology clinical trials: a review of the scope of the problem, contributing factors, and strategies to improve inclusion","volume":"66","author":"Barry","year":"2023","journal-title":"Clin. Obstet. Gynecol."},{"issue":"3","key":"10.1016\/j.ygyno.2026.08.015_bb0050","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju002","article-title":"Comparison of survival outcomes among cancer patients treated in and out of clinical trials","volume":"106","author":"Unger","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"issue":"18","key":"10.1016\/j.ygyno.2026.08.015_bb0055","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1002\/cncr.24482","article-title":"Race does not impact outcome for advanced ovarian cancer patients treated with cisplatin\/paclitaxel: an analysis of gynecologic oncology group trials","volume":"115","author":"Farley","year":"2009","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2026.08.015_bb0060","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.ygyno.2020.03.002","article-title":"Minority participation in phase 1 gynecologic oncology clinical trials: three decades of inequity","volume":"157","author":"Awad","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2026.08.015_bb0065","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1136\/ijgc-2021-002557","article-title":"Not immune to inequity: minority under-representation in immunotherapy trials for breast and gynecologic cancers","volume":"31","author":"Grette","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2026.08.015_bb0070","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ygyno.2022.01.032","article-title":"Racial and ethnic enrollment disparities in clinical trials of poly(ADP-ribose) polymerase inhibitors for gynecologic cancers","volume":"165","author":"Wagar","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.08.015_bb0075","doi-asserted-by":"crossref","DOI":"10.1097\/AOG.0000000000004917","article-title":"Enrollment of individuals from racial and ethnic minority groups in gynecologic Cancer precision oncology trials","author":"Mattei","year":"2022","journal-title":"Obstet. Gynecol."},{"issue":"11","key":"10.1016\/j.ygyno.2026.08.015_bb0080","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1136\/ijgc-2021-003088","article-title":"Recruiting for diversity in immunotherapy trials for breast and gynecologic cancers: moving beyond under-representation","volume":"31","author":"Sims","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2026.08.015_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygyno.2023.12.001","article-title":"Underrepresentation of racial and ethnic minority groups in gynecologic oncology: an analysis of over 250 trials","volume":"181","author":"Richardson","year":"2024","journal-title":"Gynecol. Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2026.08.015_bb0090","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.46494","article-title":"Racial and ethnic disparities in clinical trial enrollment among women with gynecologic Cancer","volume":"6","author":"Khadraoui","year":"2023","journal-title":"JAMA Netw. Open"},{"issue":"2","key":"10.1016\/j.ygyno.2026.08.015_bb0095","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1001\/jamasurg.2022.6600","article-title":"Race and ethnicity reporting and representation in obstetrics and gynecology clinical trials and publications from 2007\u20132020","volume":"158","author":"Steinberg","year":"2023","journal-title":"JAMA Surg."},{"issue":"3","key":"10.1016\/j.ygyno.2026.08.015_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0033677","article-title":"The database for aggregate analysis of ClinicalTrials.gov (AACT) and subsequent regrouping by clinical specialty","volume":"7","author":"Tasneem","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.ygyno.2026.08.015_bb0105","article-title":"How to avoid common problems when using ClinicalTrials.gov in research: 10 issues to consider","volume":"361","author":"Tse","year":"2018","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.ygyno.2026.08.015_bb0110","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1056\/NEJMsa1012065","article-title":"The ClinicalTrials.gov results database--update and key issues","volume":"364","author":"Zarin","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2026.08.015_bb0115","article-title":"Clinical trial design and dissemination: comprehensive analysis of ClinicalTrials.gov and PubMed data since 2005","volume":"361","author":"Zwierzyna","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.ygyno.2026.08.015_bb0125","doi-asserted-by":"crossref","unstructured":"Melchior M, Desgr\u00e9es du Lo\u00fb a, Gosselin a, et al. Migrant status, ethnicity and COVID-19: more accurate European data are greatly needed. Clin. Microbiol. Infect. Feb 2021;27(2):160\u2013162. https:\/\/doi.org\/10.1016\/j.cmi.2020.10.014.","DOI":"10.1016\/j.cmi.2020.10.014"},{"key":"10.1016\/j.ygyno.2026.08.015_bb0130","author":"NIH Policy and Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research"},{"key":"10.1016\/j.ygyno.2026.08.015_bb0135","author":"Jensen"},{"key":"10.1016\/j.ygyno.2026.08.015_bb0140","article-title":"Race\/ethnicity reporting and representation in US clinical trials: a cohort study","volume":"11","author":"Turner","year":"2022","journal-title":"Lancet Reg. Health Am."},{"issue":"2","key":"10.1016\/j.ygyno.2026.08.015_bb0145","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ygyno.2019.09.007","article-title":"Factors associated with the successful completion of randomized controlled trials in gynecological oncology","volume":"155","author":"Swailes","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.08.015_bb0150","article-title":"Determinants of publication likelihood and timeliness for clinical studies","volume":"10","author":"Wang","year":"2026","journal-title":"J Clin Transl Sci."},{"issue":"3","key":"10.1016\/j.ygyno.2026.08.015_bb0155","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/AOG.0000000000005301","article-title":"Large publication gap for gynecologic cancers in high-impact factor journals","volume":"142","author":"Sinha","year":"2023","journal-title":"Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.08.015_bb0160","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ygyno.2018.10.021","article-title":"Disparities in the allocation of research funding to gynecologic cancers by funding to lethality scores","volume":"152","author":"Spencer","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2026.08.015_bb0170","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1177\/0020731416689549","article-title":"Hospital payer and racial\/ethnic mix at private academic medical centers in Boston and new York City","volume":"47","author":"Tikkanen","year":"2017","journal-title":"Int. J. Health Serv."},{"issue":"5","key":"10.1016\/j.ygyno.2026.08.015_bb0175","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.molonc.2014.07.025","article-title":"Early phase clinical trials to identify optimal dosing and safety","volume":"9","author":"Cook","year":"2015","journal-title":"Mol. Oncol."},{"issue":"23","key":"10.1016\/j.ygyno.2026.08.015_bb0180","doi-asserted-by":"crossref","first-page":"6040","DOI":"10.1182\/bloodadvances.2022007676","article-title":"The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomes","volume":"6","author":"Faruqi","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.ygyno.2026.08.015_bb0185","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ygyno.2025.07.029","article-title":"Health equity, disparities, and barriers to cervical cancer care in the U.S.: a consensus statement by SGO, ACOG, ASCCP, ASTRO, and ABS addressing the WHO cervical Cancer elimination campaign goals related to treatment","volume":"200","author":"Neibart","year":"2025","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2026.08.015_bb0190","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1002\/cam4.5150","article-title":"Increasing patient participation in oncology clinical trials","volume":"12","author":"Chen","year":"2023","journal-title":"Cancer Med."},{"issue":"11","key":"10.1016\/j.ygyno.2026.08.015_bb0195","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJMsa1409364","article-title":"Compliance with results reporting at ClinicalTrials.gov","volume":"372","author":"Anderson","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"10221","key":"10.1016\/j.ygyno.2026.08.015_bb0200","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0140-6736(19)33220-9","article-title":"Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study","volume":"395","author":"DeVito","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ygyno.2026.08.015_bb0205","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-023-07277-1","article-title":"Quantifying the impact of the COVID-19 pandemic on clinical trial screening rates over time in 37 countries","volume":"24","author":"McDonald","year":"2023","journal-title":"Trials"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826021074?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826021074?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:42:10Z","timestamp":1789692130000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825826021074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":39,"alternative-id":["S0090825826021074"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.08.015","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early-phase vs. late-phase clinical trials in gynecologic oncology: Trends in trial completion, reporting, and enrollment of racial and ethnic minority groups","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.08.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}